Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease (INTRUST1)

July 22, 2011 updated by: Novartis Pharmaceuticals

A Randomized, Double-blind, Controlled, Parallel-group, 12-week Study to Compare the Efficacy and Safety of the Combination of Indacaterol 150 µg Once Daily With Open Label Tiotropium 18 µg Once Daily Versus Open Label Tiotropium 18 µg Once Daily in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease

This study assessed the efficacy and safety of indacaterol (150 µg once daily [od]) when combined with tiotropium (18 µg od) versus tiotropium (18 µg od) treatment alone in patients with chronic obstructive pulmonary disease (COPD)

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
1134

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Argentina
      • Buenos Aires, Argentina
        • Novartis Investigative Site
      • Cordoba, Argentina
        • Novartis Investigative Site
      • Corrientes, Argentina
        • Novartis Investigative Site
      • Mendoza, Argentina
        • Novartis Investigative Site
      • Rosario, Argentina
        • Novartis Investigative Site
  • Australia
      • Box Hill, Australia
        • Novartis Investigator Site
      • Clayton, Australia
        • Novartis Investigator Site
      • Garran, Australia
        • Novartis Investigator Site
      • Glebe, Australia
        • Novartis Investigator Site
      • Kogarah, Australia
        • Novartis Investigator Site
      • Nedlands, Australia
        • Novartis Investigator Site
  • Colombia
      • Barranquilla, Colombia
        • Novartis Investigative Site
      • Bogota, Colombia
        • Novartis Investigative Site
      • Bogota, Colombia
        • Novartis Investigator Site
      • Medellin, Colombia
        • Novartis Investigative Site
  • Denmark
      • Copenhagen, Denmark
        • Novartis Investigator Site
      • Fredericia, Denmark
        • Novartis Investigator Site
      • Silkeborg, Denmark
        • Novartis Investigator Site
      • Soeborg, Denmark
        • Novartis Investigator Site
      • Vejle, Denmark
        • Novartis Investigator Site
  • Germany
      • Berlin, Germany
        • Novartis Investigator Site
      • Cottbus, Germany
        • Novartis Investigator Site
      • Donaustauf, Germany
        • Novartis Investigator Site
      • Dortmund, Germany
        • Novartis Investigator Site
      • Erfurt, Germany
        • Novartis Investigator Site
      • Frankfurt, Germany
        • Novartis Investigator Site
      • Gelnhausen, Germany
        • Novartis Investigator Site
      • Grosshansdorf, Germany
        • Novartis Investigator Site
      • Hannover, Germany
        • Novartis Investigator Site
      • Heidelberg, Germany
        • Novartis Investigator Site
      • Leipzig, Germany
        • Novartis Investigator Site
      • Mainz, Germany
        • Novartis Investigator Site
      • Neu-Ulm, Germany
        • Novartis Investigator Site
      • Neuss, Germany
        • Novartis Investigator Site
      • Potsdam, Germany
        • Novartis Investigator Site
      • Rostock, Germany
        • Novartis Investigator Site
      • Schwabach, Germany
        • Novartis Investigator Site
      • Schwetzingen, Germany
        • Novartis Investigator Site
      • Straussberg, Germany
        • Novartis Investigator Site
      • Wiesbaden, Germany
        • Novartis Investigative Site
      • Wuppertal, Germany
        • Novartis Investigator Site
  • Guatemala
      • Guatemala, Guatemala
        • Novartis Investigative Site
      • Guatemala City, Guatemala
        • Novartis Investigative Site
  • Mexico
      • Guadalajara, Mexico
        • Novartis Investigative Site
      • Mexico City, Mexico
        • Novartis Investigator Site
      • Monterrey, Mexico
        • Novartis Investigative Site
      • Zapopan, Mexico
        • Novartis Investigative Site
  • Philippines
      • Manila, Philippines
        • Novartis Investigator Site
  • South Africa
      • Amanzimtoti, South Africa
        • Novartis Investigator Site
      • Cape Town, South Africa
        • Novartis Investigator Site
      • Johannesburg, South Africa
        • Novartis Investigator Site
      • Midrand, South Africa
        • Novartis Investigator Site
      • Umkomaas, South Africa
        • Novartis Investigator Site
  • Spain
      • Alicante, Spain
        • Novartis Investigative Site
      • Barcelona, Spain
        • Novartis Investigator Site
      • Begonte, Spain
        • Novartis Investigator Site
      • Cadiz, Spain
        • Novartis Investigator Site
      • Granollers, Spain
        • Novartis Investigator Site
      • Jaén, Spain
        • Novartis Investigative Site
      • La Coruna, Spain
        • Novartis Investigator Site
      • Leon, Spain
        • Novartis Investigator Site
      • Madrid, Spain
        • Novartis Investigator Site
      • Pamplona, Spain
        • Novartis Investigator Site
      • Torrelavega, Spain
        • Novartis Investigator Site
      • Valencia, Spain
        • Novartis Investigator Site
      • Vigo, Spain
        • Novartis Investigator Site
  • Turkey
      • Antalya, Turkey
        • Novartis Investigator Site
      • Canakkale, Turkey
        • Novartis Investigator Site
      • Isparta, Turkey
        • Novartis Investigator Site
      • Istanbul, Turkey
        • Novartis Investigator Site
      • Kartal, Turkey
        • Novartis Investigator Site
      • Kayseri, Turkey
        • Novartis Investigator Site
      • Kozlu / Zonguldak, Turkey
        • Novartis Investigator Site
      • Malatya, Turkey
        • Novartis Investigator Site
      • Manisa, Turkey
        • Novartis Investigator Site
      • Mecidiyekoy/Istanbul, Turkey
        • Novartis Investigator Site
      • Yenisehir/Izmir, Turkey
        • Novartis Investigator Site
  • United States
    • Alabama
      • Birmingham, Alabama, United States, 32509
        • Novartis Investigator Site
      • Mobile, Alabama, United States, 36608
        • Novartis Investigator Site
    • Arizona
      • Scottsdale, Arizona, United States, 85258
        • Novartis Investigative Site
      • Tucson, Arizona, United States, 85723
        • Novartis Investigative Site
      • Tucson, Arizona, United States, 85712
        • Novartis Investigative Site
    • Arkansas
      • Pine Bluff, Arkansas, United States, 71603
        • Novartis Investigator Site
    • California
      • Fountain Valley, California, United States, 92708
        • Novartis Investigator Site
      • Long Beach, California, United States, 90822
        • Novartis Investigator Site
      • Los Angeles, California, United States, 90095
        • Novartis Investigative Site
      • National City, California, United States, 91950
        • Novartis Investigator Site
      • Palmdale, California, United States, 93551
        • Novartis Investigator Site
      • Stockton, California, United States, 95207
        • Novartis Investigative Site
      • Temecula, California, United States, 92591
        • Novartis Investigator Site
    • Connecticut
      • Hartford, Connecticut, United States, 06105-1208
        • Novartis Investigative Site
    • Florida
      • Clearwater, Florida, United States, 33756
        • Novartis Investigative Site
      • Ft. Walton Beach, Florida, United States, 32547
        • Novartis Investigator Site
      • Miami, Florida, United States, 33136
        • Novartis Investigative Site
      • Miami, Florida, United States, 331577
        • Novartis Investigative Site
      • Naranja, Florida, United States, 33032
        • Novartis Investigative Site
      • Pensacola, Florida, United States, 32514
        • Novartis Investigator Site
      • Sarasota, Florida, United States, 34233
        • Novartis Investigator Site
    • Georgia
      • Atlanta, Georgia, United States, 30342
        • Novartis Investigative Site
      • Conyers, Georgia, United States, 30094
        • Novartis Investigator Site
    • Illinois
      • Normal, Illinois, United States, 61761
        • Novartis Investigative Site
    • Iowa
      • Iowa City, Iowa, United States, 52240
        • Novartis Investigative Site
    • Kansas
      • Kansas City, Kansas, United States, 66160
        • Novartis Investigative Site
      • Lenexa, Kansas, United States, 66215
        • Novartis Investigative Site
      • Topeka, Kansas, United States, 66606
        • Novartis Investigative Site
    • Louisiana
      • Lafayette, Louisiana, United States, 70503
        • Novartis Investigator Site
      • Metaire, Louisiana, United States, 70002
        • Novartis Investigator Site
      • New Orleans, Louisiana, United States, 70119
        • Novartis Investigator Site
      • Slidell, Louisiana, United States, 70458
        • Novartis Investigator Site
    • Maryland
      • Columbia, Maryland, United States, 21044
        • Novartis Investigator Site
    • Massachusetts
      • Brockton, Massachusetts, United States, 02301
        • Novartis Investigator Site
    • Michigan
      • Clarkston, Michigan, United States, 48346
        • Novartis Investigator Site
      • Detroit, Michigan, United States, 48202
        • Novartis Investigator Site
    • Missouri
      • St Charles, Missouri, United States, 63301
        • Novartis Investigative Site
    • Montana
      • Missoula, Montana, United States, 59808
        • Novartis Investigator Site
    • Nebraska
      • Boys Town, Nebraska, United States, 68010
        • Novartis Investigator Site
      • Omaha, Nebraska, United States, 68114
        • Novartis Investigative Site
      • Omaha, Nebraska, United States, 68134
        • Novartis Investigative Site
    • Nevada
      • Las Vegas, Nevada, United States, 89119
        • Novartis Investigative Site
    • New Hampshire
      • Lebanon, New Hampshire, United States, 03756
        • Novartis Investigator Site
    • New Jersey
      • Asbury Park, New Jersey, United States, 07712
        • Novartis Investigator Site
    • New York
      • Rochester, New York, United States, 14618
        • Novartis Investigative Site
    • North Carolina
      • Mooresville, North Carolina, United States, 28117
        • Novartis Investigator Site
      • Winston-Salem, North Carolina, United States, 27103
        • Novartis Investigative Site
    • Oklahoma
      • Tulsa, Oklahoma, United States, 74135-2920
        • Novartis Investigator Site
    • Oregon
      • Medford, Oregon, United States, 97504
        • Novartis Investigative Site
    • Pennsylvania
      • Bethlehem, Pennsylvania, United States, 18020
        • Novartis Investigator Site
    • Rhode Island
      • Cumberland, Rhode Island, United States, 02864
        • Novartis Investigative Site
    • South Carolina
      • Greenville, South Carolina, United States, 29615
        • Novartis Investigator Site
      • Spartanburg, South Carolina, United States, 29303
        • Novartis Investigative Site
    • Tennessee
      • Knoxville, Tennessee, United States, 37919
        • Novartis Investigator Site
    • Texas
      • El Paso, Texas, United States, 79903
        • Novartis Investigator Site
      • Houston, Texas, United States, 77024
        • Novartis Investigative Site
      • Houston, Texas, United States, 77079
        • Novartis Investigative Site
      • New Braunfels, Texas, United States, 78130-6113
        • Novartis Investigative Center
    • Virginia
      • Newport News, Virginia, United States, 23606
        • Novartis Investigator Site
      • Richmond, Virginia, United States, 23225
        • Novartis Investigative Site
      • Richmond, Virginia, United States, 23249
        • Novartis Investigator Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

40 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Diagnosis of chronic obstructive pulmonary disease (COPD) (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease [GOLD] Guidelines, 2007) and:

    1. Smoking history of at least 10 pack-years
    2. Post-bronchodilator forced expiratory volume in 1 second (FEV1) ≤ 65% and ≥ 30% of the predicted normal value
    3. Post-bronchodilator FEV1/FVC (force vital capacity) < 70%

Exclusion Criteria:

  • Patients who have had a COPD exacerbation requiring systemic glucocorticosteroid treatment or antibiotics and/or hospitalization in the 6 weeks prior to screening or during the run-in period
  • Patients who have had a respiratory tract infection within 6 weeks prior to screening or during the run-in period
  • Patients with a body mass index less than 15 or more than 40 kg/m^2
  • Patients with concomitant pulmonary disease
  • Patients with a history of asthma
  • Patients with diabetes Type I or uncontrolled diabetes Type II
  • Any patient with lung cancer or a history of lung cancer
  • Patients with a history of certain cardiovascular comorbid conditions

Other protocol-defined inclusion/exclusion criteria applied to the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Indacaterol 150 μg and tiotropium 18 μg
Patients inhaled indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Indacaterol was delivered blinded via a single dose dry powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
Drug: Indacaterol 150 μg
Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
Drug: Tiotropium 18 μg
Tiotropium was supplied in powder filled capsules together the manufacture's proprietary inhalation device (HandiHaler®).
Active Comparator: Tiotropium 18 μg
Patients inhaled placebo to indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Placebo to indacaterol was delivered blinded via a single dose dry powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
Drug: Tiotropium 18 μg
Tiotropium was supplied in powder filled capsules together the manufacture's proprietary inhalation device (HandiHaler®).
Drug: Placebo to indacaterol
Placebo to indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 8 Hours Post-dose at the End of Treatment (Week 12)
Time Frame: From 5 minutes to 8 hours post-dose at the end of treatment (Week 12, Day 84)
FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5 and 30 minutes; and 1, 2, 3, 4, 6, and 8 hours post-dose at the end of the study (Week 12, Day 84). Standardized FEV1 AUC was calculated by the trapezoidal rule. The analysis included baseline FEV1, FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.
From 5 minutes to 8 hours post-dose at the end of treatment (Week 12, Day 84)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at the End of Treatment (Week 12 + 1 Day, Day 85)
Time Frame: 24 hours post-dose at the end of treatment (Week 12 + 1 day, Day 85)
FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 23 hours 10 minutes and 23 hours 45 minutes post-dose at the end of the study (Week 12 + 1 day, Day 85). The analysis included baseline FEV1, FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.
24 hours post-dose at the end of treatment (Week 12 + 1 day, Day 85)
Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 8 Hours Post-dose on Day 1
Time Frame: From 5 minutes to 8 hours post-dose on Day 1
FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5 and 30 minutes; and 1, 2, 3, 4, 6, and 8 hours post-dose on Day 1. Standardized FEV1 AUC was calculated by the trapezoidal rule. The analysis included baseline FEV1, FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.
From 5 minutes to 8 hours post-dose on Day 1
Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose on Day 2
Time Frame: 24 hours post-dose on Day 2
FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 23 hours 10 minutes and 23 hours 45 minutes post-dose on Day 2. The analysis included baseline FEV1, FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.
24 hours post-dose on Day 2
Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 4 Hours Post-dose on Day 1
Time Frame: From 5 minutes to 4 hours post-dose on Day 1
FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5 and 30 minutes; and 1, 2, 3, and 4 hours post-dose on Day 1. Standardized FEV1 AUC was calculated by the trapezoidal rule. The analysis included baseline FEV1, FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.
From 5 minutes to 4 hours post-dose on Day 1
Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 4 Hours Post-dose at the End of Treatment (Week 12)
Time Frame: From 5 minutes to 4 hours post-dose at the end of treatment (Week 12)
FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5 and 30 minutes; and 1, 2, 3, and 4 hours post-dose at the end of treatment (Week 12). Standardized FEV1 AUC was calculated by the trapezoidal rule. The analysis included baseline FEV1, FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.
From 5 minutes to 4 hours post-dose at the end of treatment (Week 12)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Novartis Pharmaceuticals

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 1, 2009

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 1, 2010

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 1, 2010

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 15, 2009

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 15, 2009

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 18, 2009

Study Record Updates

Last Update Posted (Estimate)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 18, 2011

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 22, 2011

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2011

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • CQAB149B2341

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings